Shift Toward Highly Profitable Branded Drugs and Biosimilars
First written in FY2016-Q3. 21 of 31 entries say "Restated". Latest entry: 2026-09-16.
0 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「For biosimilars, in addition to focusing on ustekinumab BS subcutaneous injection 45 mg “F,” a psoriasis treatment launched in May 2024, the company submitted applications for marketing approval for 1 product in September 2024 and 2 products in October 2024, and is moving forward with further expansion of its biosimilars business.」
Regarding its biosimilars initiatives, the company documents concrete progress, including the launch of ustekinumab BS subcutaneous injection 45 mg “F” and the submission of marketing approval applications for 1 product in September 2024 and 2 products in October 2024. - FY2024-Q1RestatedAnnual report
「As part of its growth strategy toward 2030, the entire Group is working to enhance the pipeline of new drugs, biosimilars and generics so that it can expand further over the following 5 years.」
The company continues to expand the pipeline of new drugs, biosimilars and generics as part of its growth strategy toward 2030. - FY2023-Q3RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues its product and development policy, including enhancing the pipeline of new drugs, biosimilars and generics, as part of its growth strategy toward 2030. - FY2023-Q2RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues to expand the pipeline of new drugs, biosimilars and generics as part of its growth strategy toward 2030. - FY2023-Q1RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues its policy of enhancing the pipeline of new drugs, biosimilars and generics as part of its growth strategy toward 2030. - FY2022RestatedAnnual report
「As part of our growth strategy toward 2030, the entire Group is working to enhance its pipeline of new drugs, biosimilars and generics, among other initiatives.」
The company continues its policy of expanding the development pipeline, including new drugs, biosimilars and generics. - FY2022-Q3RestatedAnnual report
「As part of our growth strategy toward 2030, the entire Group is working to enhance its pipeline of new drugs, biosimilars and generics, among other initiatives.」
The company continues to document its policy of expanding the pipeline, including new drugs, biosimilars and generics. - FY2022-Q2RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues its product and development policy, including enhancing the pipeline of new drugs, biosimilars and generics. - FY2022-Q1RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues its product and development policy, including enhancing the pipeline of new drugs, biosimilars and generics. - FY2021RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues its product and development policy, including expanding the pipeline of new drugs, biosimilars and generics. - FY2021-Q3RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues to document its product and development policy, including enhancing the pipeline of new drugs, biosimilars and generics. - FY2021-Q2RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The company continues to document its product mix and development policy, including enhancing the pipeline of new drugs, biosimilars and generics, as it did in the previous quarter. - FY2021-Q1RestatedAnnual report
「Under this medium-term management plan, themed "Fujiらしくをあたらしく," the Group is pursuing a growth strategy toward 2030 by strengthening its core areas of women's healthcare and acute care, actively entering overseas markets such as ASEAN and North America with a sense of urgency, and enhancing its pipeline of new drugs, biosimilars, and generics so that it can expand further over the following five years.」
The former policy of shifting toward branded drugs and biosimilars continues within the framework of the new medium-term management plan, which includes enhancing the pipeline of new drugs, biosimilars and generics. - FY2020ReframedAnnual report
「As part of our growth strategy toward 2030, the entire Group is working to enhance its pipeline of new drugs, biosimilars and generics, among other initiatives.」
The former direction of shifting toward branded drugs and biosimilars has been reorganized within the framework of the new medium-term plan as the enhancement of the overall pipeline, including new drugs, biosimilars and generics. - FY2019AdvancedAnnual report
「As a result, we achieved a measure of progress, including the development of branded drugs through in-licensing from European companies Mithra and Besins Healthcare, and the expansion of the business of our subsidiary OLIC (Thailand) Limited.」
Regarding the shift toward branded drugs, the company identifies the development of branded drugs through in-licensing from European companies as concrete progress. - FY2019-Q3RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2019-Q2RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2019-Q1RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2018-Q3RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2018-Q2RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2018-Q1RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2017RaisedAnnual report
「We will move beyond our historically generic-focused business and build our business plans and management strategy around existing products supplemented by new branded drugs, namely new drugs, branded generics (long-listed products) and biosimilars.」
The policy of shifting toward branded drugs and biosimilars has been clarified as a move beyond a generic-focused business toward building a new business stage and operating structure centered on branded drugs. - FY2017-Q3RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2017-Q2RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2017-Q1RestatedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company continues to identify shifting its product mix toward highly profitable branded drugs, biosimilars and other products as a challenge. - FY2016-Q3First statedAnnual report
「Shifting toward highly profitable branded drugs, biosimilars and other products」
The company documents a shift in its product mix toward branded drugs, biosimilars and other products.